Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.
Friedberg S, Choi D, Hunold T, Choi NK, Garcia NM, Picker EA, Cohen NA, Cohen RD, Dalal SR, Pekow J, Sakuraba A, Krugliak Cleveland N, Rubin DT. Friedberg S, et al. Among authors: rubin dt. Clin Gastroenterol Hepatol. 2023 Jul;21(7):1913-1923.e2. doi: 10.1016/j.cgh.2023.03.001. Epub 2023 Mar 8. Clin Gastroenterol Hepatol. 2023. PMID: 36898598 Free PMC article.
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group. Regueiro M, et al. Gastroenterology. 2016 Jun;150(7):1568-1578. doi: 10.1053/j.gastro.2016.02.072. Epub 2016 Mar 3. Gastroenterology. 2016. PMID: 26946343 Free article. Clinical Trial.
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT. Christensen B, et al. Among authors: rubin dt. Aliment Pharmacol Ther. 2018 Mar;47(6):753-762. doi: 10.1111/apt.14525. Epub 2018 Jan 29. Aliment Pharmacol Ther. 2018. PMID: 29377235 Free PMC article.
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development.
Reinisch W, Gottlieb K, Colombel JF, Danese S, Panaccione R, Panes J, Peyrin-Biroulet L, Rubin D, Sands BE, Schreiber S, Vermeire S, Mulberg A, Sandborn B. Reinisch W, et al. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1673-1679.e1. doi: 10.1016/j.cgh.2018.10.032. Epub 2018 Oct 26. Clin Gastroenterol Hepatol. 2019. PMID: 31352970 Review.
Ultrasonographic Transmural Healing in Crohn's Disease.
Zorzi F, Rubin DT, Cleveland NK, Monteleone G, Calabrese E. Zorzi F, et al. Among authors: rubin dt. Am J Gastroenterol. 2023 Jun 1;118(6):961-969. doi: 10.14309/ajg.0000000000002265. Epub 2023 Mar 28. Am J Gastroenterol. 2023. PMID: 36988302 Review.
Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.
Wong SY, Wellens J, Helmus D, Marlow L, Brann S, Martinez Pazos V, Weinberg A, Moran HR, McGregor C, Vermeire S, Watanabe K, Kamikozuru K, Ahuja V, Vermani S, Lindsay JO, Kingston A, Dutta U, Kaur H, Silverberg MS, Milgrom R, Chien Ng S, Mak JWY, Cadwell K, Thompson C, Colombel JF, Satsangi J; ICARUS-IBD Consortium. Wong SY, et al. Inflamm Bowel Dis. 2023 Nov 2;29(11):1693-1705. doi: 10.1093/ibd/izad097. Inflamm Bowel Dis. 2023. PMID: 37354560
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Among authors: rubin dt. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Inflammation in the proximal colon is a risk factor for the development of colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis.
Jamil OK, Shaw D, Deng Z, Dinardi N, Fillman N, Khanna S, Krugliak Cleveland N, Sakuraba A, Weber CR, Cohen RD, Dalal S, Jabri B, Rubin DT, Pekow J. Jamil OK, et al. Among authors: rubin dt. Therap Adv Gastroenterol. 2023 Sep 7;16:17562848231184985. doi: 10.1177/17562848231184985. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 37692199 Free PMC article.
482 results